Thrombosis
Conference Coverage
Anticoagulants may have advantage over aspirin for low-risk TAVR
NATIONAL HARBOR, MD. – Anticoagulant therapy is found superior to antiplatelet therapy for preventing leaflet thrombosis after TAVR.
Conference Coverage
AFib patients do best on a DOAC started 7-10 days post stroke
LOS ANGELES – Observational data hints at the best time to start oral anticoagulation in AFib patients after a cardioembolic stroke.
Commentary
The evolving landscape of complement inhibition therapy
The surge of new complement inhibitors could revolutionize our strategy for treatment of autoimmune-mediated diseases.
Conference Coverage
Are providers asking about menstrual bleeding before/during anticoagulant therapy?
Conference Coverage
Bariatric surgery candidates show high prevalence of thrombophilia
LAS VEGAS –
Conference Coverage
New ASH guideline: VTE prophylaxis after major surgery
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...
Conference Coverage
Aspirin plus a DOAC may do more harm than good in some
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication...
News
Pulmonary embolism treatment teams adopted widely for complex disease
Conference Coverage
GALILEO, GALILEO 4D: Mixed results in post-TAVR anticoagulation
Conference Coverage
Thromboembolic events more likely among CIDP patients with CVAD
AUSTIN, TEX. – Although the study matched patients by demographic factors, researchers did not adjust the analysis for risk factors or confounders...
News from the FDA/CDC
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.